As Axcella’s Chief Scientific Officer, Tony Tramontin, Ph.D., leads Research and Development activities including discovery, preclinical development, technical development, formulation, and strategic innovation.

Prior to Axcella, Dr. Tramontin was a Partner in McKinsey & Company’s Global Healthcare Practice. Across a 13-year career with the firm, he advised biopharma executive teams on a wide variety of strategic, operational and organizational topics across the value chain. The majority of his work, however, focused specifically on research, medicine development and early aspects of commercialization. He co-founded and led McKinsey’s technical service line that helps biopharma executives with R&D project investment decisions, portfolio prioritization, risk management, therapeutic area strategy, and product launch strategy.

Before joining McKinsey, Dr. Tramontin was an experimental neuroscientist conducting neural stem cell research at The Rockefeller University and The University of California San Francisco Department of Neurosurgery.